Related Experiment Video
Updated: Oct 29, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Abstract:
Patients with previously treated KRAS G12C-mutated non-small cell lung cancer who received the KRASG12C inhibitor divarasib were 42% less likely to experience disease recurrence or die than those who received the standard first-generation drugs sotorasib or adagrasib, an international phase III trial concluded. After a median follow-up of 14.3 months, the median progression-free survival was 9.8 months and 5.7 months, respectively.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Inhibitors Of Virion Release
Antihypertensive Drugs: Direct Renin Inhibitors
The Ras Gene
Ras is a superfamily...